The liver cirrhosis market involves treatment approaches and drugs for cirrhosis of the liver. Cirrhosis refers to the scarring and eventual fibrosis of the liver caused by long-term damage to the liver cells due to various conditions like excessive alcohol use, hepatitis B and C infections, fatty liver disease, etc. It impairs the liver’s ability to function properly in filtering toxins and aiding digestion.
The main treatment in the Liver Cirrhosis Market involves minimizing further damage to the liver through removing the underlying causes, providing nutrition support, and managing symptoms and complications.
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
Key players operating in the liver cirrhosis market are Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., and Roche. The key opportunities in the market include rising awareness about early diagnosis and management, growing healthcare expenditures in developing nations, and an increasing number of clinical trials evaluating new drug candidates and alternative therapies. The major players are focusing on global expansion through collaborations and acquisitions to strengthen their product portfolios and geographical presence. For instance, in 2021, Gilead Sciences acquired MYR GmbH to develop novel liver disease treatments.
Market Drivers Rising alcohol consumption is a major driver boosting the liver cirrhosis market growth. Excessive alcohol intake contributes to nearly 50% of cirrhosis cases worldwide. With changing lifestyles and social drinking becoming increasingly common, alcohol consumption is rising steadily.
Market Restrain However, the high cost of treatment procedures and therapies act as a major restraint. Liver transplantation and new drug approvals involve significant R&D investments pushing up treatment costs. This makes advanced care inaccessible in low and middle-income markets.
Segment Analysis: The liver cirrhosis market is segmented based on drug class and sales channel. The ascites segment dominates the market currently as it accounts for the majority of cases of liver cirrhosis. Ascites occurs when fluid builds up in the spaces between tissues in the abdomen due to severe scarring of the liver. Another major segment is variceal bleeding which occurs when enlarged blood vessels in the esophagus or stomach burst. This is a medical emergency which requires immediate treatment and has driven the growth of this segment.
Global Analysis: North America dominates the liver cirrhosis market currently due to growing alcohol consumption and rising prevalence of non-alcoholic fatty liver disease (NAFLD) in the region. According to the Centers for Disease Control and Prevention in the US, excessive drinking is responsible for around 1 in 5 deaths from cirrhosis. However, the Asia Pacific region is expected to grow the fastest in the coming years due to changing lifestyles, rising obesity rates and growing consumption of junk food in developing nations like India and China leading to NAFLD and other chronic liver conditions. Countries like Japan, South Korea and Australia also have a high prevalence of liver disease and cirrhosis due to excessive alcohol intake.
Get this Report in Japanese Language: č‚ťçˇ¬ĺ¤‰ĺ¸‚ĺ ´
Get this Report in Korean Language: 간경변 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
